Omega Healthcare Investors (OHI - Free Report) reported $144.85 million in revenue for the quarter ended December 2022, representing a year-over-year decline of 42.1%. EPS of $0.73 for the same period compares to $0.14 a year ago.
The reported revenue represents a surprise of -6.11% over the Zacks Consensus Estimate of $154.28 million. With the consensus EPS estimate being $0.73, the company has not delivered EPS surprise.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Omega Healthcare Investors performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Rental income: $110.15 million versus the four-analyst average estimate of $144.81 million. The reported number represents a year-over-year change of -48.6%.
- Income from direct financing leases: $0.26 million compared to the $0.24 million average estimate based on three analysts. The reported number represents a change of -0.8% year over year.
- Real estate tax and ground lease income: $4.16 million versus $4.41 million estimated by three analysts on average.
- Diluted- Net income (loss): $0.19 versus $0.25 estimated by four analysts on average.
View all Key Company Metrics for Omega Healthcare Investors here>>>
Shares of Omega Healthcare Investors have returned +3.9% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Omega Healthcare Investors (OHI - Free Report) reported $144.85 million in revenue for the quarter ended December 2022, representing a year-over-year decline of 42.1%. EPS of $0.73 for the same period compares to $0.14 a year ago.
The reported revenue represents a surprise of -6.11% over the Zacks Consensus Estimate of $154.28 million. With the consensus EPS estimate being $0.73, the company has not delivered EPS surprise.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Omega Healthcare Investors performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
View all Key Company Metrics for Omega Healthcare Investors here>>>
Shares of Omega Healthcare Investors have returned +3.9% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on OHI - FREE